Taiwan Liposome Company, which is developing lipid formulations of approved drugs for pain and eye disease, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The Taipei City, Taiwan-based company was founded in 1997 and booked $2 million in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol TLC. Taiwan Liposome Company filed confidentially on December 8, 2017. Cantor Fitzgerald is the sole bookrunner on the deal. No pricing terms were disclosed.
